$50 million new gift to hospital will accelerate a new era of gene and cell therapy–driven cancer care
Mass General Brigham is heralding a landmark $50 million philanthropic commitment that executives say will accelerate a new era of gene and cell therapy–driven cancer care across New England and beyond.
David Ryan, MD, President of the Mass General Brigham Cancer Institute announced that the gift is being channeled through the work of physician‑scientists, clinical leaders, and builders whose identities now anchor the health system’s most ambitious cancer agenda to date.
The commitment arrives as Mass General Brigham advances a bold, system‑wide vision for the future of cancer care built around gene and cell therapies, next‑generation clinical trials, and a “for every patient” approach that links its academic medical centers and community hospitals into a unified research and care platform. The $50 million will underwrite highly specialized spaces and infrastructure—from apheresis suites where immune cells are collected, to a dedicated cell pharmacy capable of engineering those cells into living medicines—alongside new programs and talent focused on diseases once considered beyond the reach of curative treatment.
David F. M. Brown, MD, President of Academic Medical Centers for Mass General Brigham, has described the support as “transformative,” emphasizing that to cure disease and alleviate suffering, the system must equip “the world’s best minds” with resources to push the boundaries of science.
The gift builds on momentum generated by early‑stage breakthroughs already emerging from Mass General Brigham’s laboratories and cancer clinics. Researchers at the Mass General Cancer Center—one of the core anchors of the Mass General Brigham Cancer Institute—recently reported striking early results from a first‑in‑human clinical trial using CAR T‑cell therapy to target glioblastoma, an aggressive brain tumor with historically poor outcomes. In work led by investigators including neurologist‑oncologists such as Elizabeth Gerstner, MD, teams have been testing novel CAR‑T designs that simultaneously target multiple tumor antigens and recruit the broader immune system against glioblastoma. Early data shared at major oncology meetings have demonstrated successful manufacturing of patient‑specific CAR T products, persistence of engineered cells in cerebrospinal fluid, and dynamic changes in immune cell populations following treatment—signals that donors and institutional leaders point to as evidence that targeted philanthropic capital can bend the curve of once‑intractable diseases.
For patients and families following these developments, gene and cell therapies can sound abstract, but Mass General Brigham is framing the $50 million as a direct investment in concrete capabilities. Gene therapy uses carefully designed genetic material to change how cells produce proteins, with the aim of boosting the body’s ability to fight disease or reducing the impact of harmful processes. Cell therapy starts with intact human cells—either from the patient or a donor—that are modified or expanded outside the body and then returned to repair or replace damaged tissue and mount targeted attacks on malignancies. In blood cancers such as specific leukemias and lymphomas, CAR T‑cell therapy has already transformed expectations, turning some diagnoses once viewed as uniformly fatal into conditions where durable remission is now a realistic goal.
Mass General Brigham’s leadership argues that the same underlying approaches are now poised to reshape care for a wider set of conditions, including solid tumors like glioblastoma, autoimmune diseases, lung diseases, stroke, spinal cord injuries, and neurodegenerative disorders. The new philanthropy is structured to accelerate that expansion by funding advanced apheresis capabilities and cell‑processing laboratories across the system, supporting a portfolio of early‑ and mid‑stage gene and cell therapy trials, and enabling the recruitment of global leaders whose expertise spans laboratory science, trial design, and complex patient care. David Ryan, MD, President of the Mass General Brigham Cancer Institute, notes that the institute is already home to thousands of experts who “every day drive new breakthroughs and innovations to transform care and save lives,” and has called the gift a “remarkable opportunity” to redefine the future of diseases once deemed incurable, including cancer and autoimmune conditions.
The timing and structure of the gift reflect a larger, multiyear effort to recast Mass General Brigham Cancer as an integrated enterprise capable of moving discoveries from bench to bedside at scale. The organization, which includes several Harvard Medical School teaching hospitals, has articulated a cancer strategy built around unified clinical pathways, precision oncology, and a robust research engine supported by hundreds of millions of dollars in annual funding. Recent capital projects such as the Herb Chambers Tower at Massachusetts General Hospital and expanded programs at the Hale Building for Transformative Medicine at Brigham and Women’s Hospital are designed to house multidisciplinary clinics, infusion centers, and research programs under one roof, creating the physical backbone for a highly coordinated cancer network. Within this context, the $50 million infusion is less an isolated windfall than a catalytic component of a broader capital stack that includes institutional investment, federal research grants, industry partnerships, and additional philanthropy.
Although the benefactors behind the $50 million have chosen not to be named, they have, according to Mass General Brigham, been explicit about their motivations. The gift is being made in deep gratitude for care provided by teams across the system and with a clear intention to ensure that future patients benefit from therapies that did not exist when their own journeys began. That choice places additional feasibility on visible leaders like Brown and Ryan—and on the clinicians, investigators, and staff whose work will be funded—to serve as the public faces of the philanthropy, narrating how the investment is being translated into new spaces, trials, and treatments.
The public rollout has been orchestrated by Mass General Brigham’s communications and development leadership, including executives such as Mike Morrison, Senior Director of External Communications for the system’s hospitals, who is coordinating media engagement around the announcement. Coverage across institutional channels, local business media, and professional networks has framed the commitment as both a vote of confidence in Mass General Brigham’s existing cancer strategy and an invitation to other philanthropists to match the ambition it represents. For the thousands of patients entering Mass General Brigham clinics and hospitals each day, much of the work funded by the $50 million will unfold behind the scenes in laboratories, clean rooms, and data centers, but as more clinical trials open and more patients gain access to gene and cell therapies designed in Boston and delivered close to home, the impact of this anonymous generosity will be measured in very personal terms.